Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 6/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | TNK2 | Q07912 | 7/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | WEE1 | P30291 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.36 |
| ▸ | CDK4 | P11802 | 2/20 | 0.36 |
| ▸ | CCND1 | P24385 | 2/20 | 0.36 |
| ▸ | CDK9 | P50750 | 2/20 | 0.36 |
| ▸ | CCND3 | P30281 | 1/20 | 0.36 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | PAK3 | O75914 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15041346 | 0.93 | FGFR1 (0.41) | FGFR1FGFR4KDRJAK3MAPK9 | |
| SCHEMBL15035386 | 0.85 | MAPK9 (0.39) | FGFR1FGFR4KDRJAK3MAPK9 | |
| SCHEMBL15041297 | 0.79 | MAPK9 (0.40) | FGFR1FGFR4KDRJAK3MAPK9 | |
| SCHEMBL15035306 | 0.77 | CDK4 (0.46) | FGFR1FGFR4KDRFLT3CCNT1 | |
| SCHEMBL15035420 | 0.76 | FGFR1 (0.40) | FGFR1FGFR4KDRJAK3MAPK9 | |
| SCHEMBL15034965 | 0.76 | JAK3 (0.41) | FGFR1FGFR4KDRJAK3MAPK9 | |
| SCHEMBL15035764 | 0.75 | JAK3 (0.39) | FGFR1FGFR4KDRJAK3MAPK9 | |
| SCHEMBL15041586 | 0.74 | FGFR1 (0.41) | FGFR1FGFR4KDRJAK3MAPK9 | |
| SCHEMBL15035304 | 0.74 | FGFR1 (0.40) | FGFR1FGFR4KDRJAK3MAPK9 | |
| SCHEMBL15034857 | 0.73 | JAK3 (0.39) | FGFR1FGFR4KDRJAK3MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | FGFR1 1919/4885FGFR4 1949/4885KDR 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.